Galectin-3 as a novel biotarget in cardiovascular alterations associated to development of severe aortic stenosis

Area of Science:

• Cardiovascular Medicine
• Biomedical Research
• Pathophysiology

Background:

• Aortic stenosis is a prevalent valvular heart disease and a leading cause of heart failure in older adults.
• Current management for severe symptomatic aortic stenosis relies on valve replacement, as no medical therapies exist to halt disease progression.
• The disease involves complex valve pathology and compensatory cardiac and vascular changes due to chronic pressure overload.

Purpose of the Study:

• To review current literature on the role of Galectin-3 in aortic stenosis.
• To evaluate Galectin-3 as a potential therapeutic target for aortic valve disease and associated cardiovascular alterations.

Main Methods:

• Literature review of recent studies on Galectin-3.
• Analysis of Galectin-3's involvement in biological processes relevant to aortic stenosis.
• Synthesis of evidence regarding Galectin-3's impact on valve and cardiovascular changes.

Main Results:

• Galectin-3 is implicated in key biological functions including inflammation and fibrosis.
• Emerging evidence suggests Galectin-3 plays a role in the structural and biological changes of aortic stenosis.
• The protein's involvement in cardiovascular alterations associated with the disease is increasingly recognized.

Conclusions:

• Galectin-3 represents a promising therapeutic target for aortic stenosis.
• Targeting Galectin-3 may offer a novel medical approach to manage aortic valve disease and its cardiovascular consequences.
• Further research is warranted to fully elucidate Galectin-3's therapeutic potential.